Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 30:e70097.
doi: 10.1111/jsr.70097. Online ahead of print.

The Effectiveness of Melatonin for Sleep Disturbances in Parkinson' Disease: Systematic Review and Meta-Analysis

Obai Yousef  1 , Moaz Elsayed Abouelmagd  2 , Hala Khaddam  1 , Abdulrahman Shbani  1 , Raneem Yousef  1 , Mostafa Meshref  3 , Ibrahem Hanafi  4
Affiliations
Review

The Effectiveness of Melatonin for Sleep Disturbances in Parkinson' Disease: Systematic Review and Meta-Analysis

Obai Yousef et al. J Sleep Res. .

Abstract

Sleep disturbances in Parkinson's disease (PD) reduce quality of life. Melatonin, a sleep-wake hormone, shows treatment potential. However, its efficacy in PD remains unclear due to inconclusive findings across studies, warranting a systematic review to synthesise the available evidence. We searched PubMed, Cochrane, Web of Science, and Scopus for RCTs up to May 2025. Study quality was evaluated using the Cochrane Rob-2 tool. Statistical analysis was conducted using Review Manager version 5.4.1 with outcomes expressed as mean differences (MD) with 95% confidence intervals (CI). Out of eight studies with 409 PD patients, seven studies entered a meta-analysis that showed melatonin improved sleep quality and insomnia, as indicated by Pittsburgh Sleep Quality Index (PSQI) (MD = -1.75 [-2.94 to -0.55]; p = 0.004) and Epworth Sleepiness Scale (ESS) (MD = -1.07 [-1.87 to -0.27]; p = 0.009). Melatonin showed no significant impact on objective sleep parameters. However, sleep onset latency (MD = -9.74 [-17.47 to -2.02]; p = 0.001) and total sleep time (SMD = 0.84 [0.47 to 1.21]; p < 0.00001) improved, favouring melatonin, after adjusting for heterogeneity. Melatonin did not significantly change REM Sleep Behaviour Disorder Screening Questionnaire (RBDSQ) (MD = 0.71 [-0.44 to 1.86]; p = 0.23). No significant differences was found between melatonin and clonazepam in ESS (MD = -2.65 [-5.36 to 0.06]; p = 0.06). In conclusion, melatonin is a well-tolerated treatment that improves sleep quality, sleep onset latency, and total sleep time in PD. However, improvements in subjective sleep quality assessments did not meet minimal clinically important difference, which limits the clinical significance of these findings. Additional research is required to determine whether these benefits translate to other objective sleep parameters.

Keywords: Parkinson' disease; efficacy; insomnia; melatonin; sleep.

PubMed Disclaimer

References

    1. Adler, C. H., J. N. Caviness, J. G. Hentz, M. Lind, and J. Tiede. 2003. “Randomized Trial of Modafinil for Treating Subjective Daytime Sleepiness in Patients With Parkinson's Disease.” Movement Disorders 18: 287–293. https://doi.org/10.1002/mds.10390.
    1. Ahn, J. H., M. Kim, S. Park, et al. 2020. “Prolonged‐Release Melatonin in Parkinson's Disease Patients With a Poor Sleep Quality: A Randomized Trial.” Parkinsonism & Related Disorders 75: 50–54. https://doi.org/10.1016/j.parkreldis.2020.03.029.
    1. Buysse, D. J., M. L. Hall, P. J. Strollo, et al. 2008. “Relationships Between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and Clinical/Polysomnographic Measures in a Community Sample.” Journal of Clinical Sleep Medicine 4, no. 6: 563–571.
    1. Daneshvar Kakhaki, R., V. Ostadmohammadi, E. Kouchaki, et al. 2020. “Melatonin Supplementation and the Effects on Clinical and Metabolic Status in Parkinson's Disease: A Randomized, Double‐Blind, Placebo‐Controlled Trial.” Clinical Neurology and Neurosurgery 195: 105878. https://doi.org/10.1016/j.clineuro.2020.105878.
    1. De Lau, L. M., and M. M. Breteler. 2006. “Epidemiology of Parkinson's Disease.” Lancet Neurology 5: 525–535. https://doi.org/10.1016/S1474‐4422(06)70471‐9.